search button
Open Access

Caffeoylxanthiazonoside exerts cardioprotective effects during chronic heart failure via inhibition of inflammatory responses in cardiac cells

  • Authors:
    • Bin Yang
    • Fei Wang
    • Huili Cao
    • Guifang Liu
    • Yuean Zhang
    • Ping Yan
    • Bao Li

  • View Affiliations

  • Published online on: August 31, 2017     https://doi.org/10.3892/etm.2017.5080
  • Pages: 4224-4230

  • Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Caffeoylxanthiazonoside (CYT) is an active constituent isolated from the fruit of the Xanthium strumarium L plant. The aim of the present study was to investigate the cardioprotective effects of oral administration of CYT on chronic heart failure (CHF) and its underlying mechanisms. A rat model of CHF was first established, and cardiac function indices, including the heart/body weight index, left heart/body weight index, fractional shortening (FS), ejection fraction (EF), cardiac output (CO) and heart rate (HR), were subsequently determined by cardiac ultrasound. Serum levels of lactate dehydrogenase (LDH) and creatine kinase (CK), and the levels of pro‑inflammatory cytokines, including tumor necrosis factor (TNF)‑α, interleukin (IL)‑6 and IL‑1β in heart tissues and cardiac microvascular endothelial cells (CMECs) were determined using ELISA. In addition, the protein expression levels of nuclear factor‑κB (NF‑κB) signaling pathway members were determined by western blotting in CMECs. The results demonstrated that oral administration of 10, 20, 40 mg/kg CYT significantly reduced cardiac hypertrophy and reversed FS, EF, CO and HR when compared with CHF model rats. In addition, CYT administration significantly decreased the levels of TNF‑α, IL‑6 and IL‑1β in heart tissues, as well as serum LDH and CK levels. Furthermore, exposure of CMECs to 20, 40 and 80 µg/ml CYT significantly decreased the production of TNF‑α, IL‑1β and IL‑6. The protein expression levels of cytoplasmic NF‑κB p65 and IκB were upregulated, while nuclear NF‑κB p65 was downregulated following treatment of CMECs with 20, 40 and 80 µg/ml CYT when compared with untreated CHF model controls. In conclusion, the results of the current study suggest that CYT demonstrates cardioprotective effects in CHF model rats by suppressing the expression of pro‑inflammatory cytokines and the NF‑κB signaling pathway.
View Figures
View References

Related Articles

Journal Cover

November-2017
Volume 14 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.4
  • Ranked Medicine Research and Experimental
    (total number of cites)
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Yang B, Wang F, Cao H, Liu G, Zhang Y, Yan P and Li B: Caffeoylxanthiazonoside exerts cardioprotective effects during chronic heart failure via inhibition of inflammatory responses in cardiac cells. Exp Ther Med 14: 4224-4230, 2017.
APA
Yang, B., Wang, F., Cao, H., Liu, G., Zhang, Y., Yan, P., & Li, B. (2017). Caffeoylxanthiazonoside exerts cardioprotective effects during chronic heart failure via inhibition of inflammatory responses in cardiac cells. Experimental and Therapeutic Medicine, 14, 4224-4230. https://doi.org/10.3892/etm.2017.5080
MLA
Yang, B., Wang, F., Cao, H., Liu, G., Zhang, Y., Yan, P., Li, B."Caffeoylxanthiazonoside exerts cardioprotective effects during chronic heart failure via inhibition of inflammatory responses in cardiac cells". Experimental and Therapeutic Medicine 14.5 (2017): 4224-4230.
Chicago
Yang, B., Wang, F., Cao, H., Liu, G., Zhang, Y., Yan, P., Li, B."Caffeoylxanthiazonoside exerts cardioprotective effects during chronic heart failure via inhibition of inflammatory responses in cardiac cells". Experimental and Therapeutic Medicine 14, no. 5 (2017): 4224-4230. https://doi.org/10.3892/etm.2017.5080